Seeking Alpha

Jazz Pharmaceuticals (JAZZ) gains 3.1% AH after guiding for 2012 revenue of $465M-$490M and EPS...

Jazz Pharmaceuticals (JAZZ) gains 3.1% AH after guiding for 2012 revenue of $465M-$490M and EPS of $4-$4.15, above a consensus of $462.8M and $3.40. The guidance takes into account Jazz's planned merger with Azur Pharma, which the companies hope to close on Jan. 16 - it's possible not all analyst forecasts took the deal into account.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|